# Fatpipe Inc: financial statements, quarterly

FATN · Nasdaq · CIK 1993400 · [Technology](/sectors/technology.md) · fiscal year ends Mar 31

Pages: [Overview](/companies/fatn.md) · [Financials](/companies/fatn/financials.md) · [Filings](/companies/fatn/filings.md) · [Insiders](/companies/fatn/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/fatn/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2024-06-30) | period not labelled (2024-09-30) | period not labelled (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [3,750](/filings/0001641172-25-021487.md) | [5,596](/filings/0001493152-25-020604.md) | [3,149](/filings/0001493152-26-004738.md) | [3,794 d](/filings/0001493152-26-024184.md) | [3,936](/filings/0001493152-26-035447.md) | [3,959](/filings/0001493152-25-020604.md) | [4,088](/filings/0001493152-26-004738.md) | [7,225 d](/filings/0001493152-26-024184.md) | [5,032](/filings/0001493152-26-035447.md) |
| Cost of revenue | $k | [284](/filings/0001641172-25-021487.md) | [229](/filings/0001493152-25-020604.md) | [380](/filings/0001493152-26-004738.md) | [169 d](/filings/0001493152-26-024184.md) | [227](/filings/0001493152-26-035447.md) | [313](/filings/0001493152-25-020604.md) | [504](/filings/0001493152-26-004738.md) | [685 d](/filings/0001493152-26-024184.md) | [390](/filings/0001493152-26-035447.md) |
| Gross profit | $k | [3,467](/filings/0001641172-25-021487.md) | [5,366](/filings/0001493152-25-020604.md) | [2,769](/filings/0001493152-26-004738.md) | [3,626 d](/filings/0001493152-26-024184.md) | [3,709](/filings/0001493152-26-035447.md) | [3,646](/filings/0001493152-25-020604.md) | [3,584](/filings/0001493152-26-004738.md) | [6,541 d](/filings/0001493152-26-024184.md) | [4,641](/filings/0001493152-26-035447.md) |
| Research and development | $k | not reported | not reported | [449](/filings/0001493152-26-004738.md) | [480 d](/filings/0001493152-26-024184.md) | [474](/filings/0001493152-26-035447.md) | not reported | [454](/filings/0001493152-26-004738.md) | [488 d](/filings/0001493152-26-024184.md) | [527](/filings/0001493152-26-035447.md) |
| Operating income | $k | [860](/filings/0001641172-25-021487.md) | [2,263](/filings/0001493152-25-020604.md) | [185](/filings/0001493152-26-004738.md) | [164 d](/filings/0001493152-26-024184.md) | [1,003](/filings/0001493152-26-035447.md) | [(0.8)](/filings/0001493152-25-020604.md) | [402](/filings/0001493152-26-004738.md) | [2,185 d](/filings/0001493152-26-024184.md) | [901](/filings/0001493152-26-035447.md) |
| Interest expense | $k | [86.0](/filings/0001641172-25-021487.md) | [86.4](/filings/0001493152-25-020604.md) | [118](/filings/0001493152-26-004738.md) | [39.4 d](/filings/0001493152-26-024184.md) | [69.9](/filings/0001493152-26-035447.md) | [126](/filings/0001493152-25-020604.md) | [104](/filings/0001493152-26-004738.md) | [103 d](/filings/0001493152-26-024184.md) | [95.1](/filings/0001493152-26-035447.md) |
| Income tax | $k | [163](/filings/0001641172-25-021487.md) | [551](/filings/0001493152-25-020604.md) | [60.1](/filings/0001493152-26-004738.md) | [520 d](/filings/0001493152-26-024184.md) | [215](/filings/0001493152-26-035447.md) | [(12.6)](/filings/0001493152-25-020604.md) | [90.2](/filings/0001493152-26-004738.md) | [(1,776) d](/filings/0001493152-26-024184.md) | [(371)](/filings/0001493152-26-035447.md) |
| Net income | $k | [625](/filings/0001641172-25-021487.md) | [1,611](/filings/0001493152-25-020604.md) | [84.4](/filings/0001493152-26-004738.md) | [(355) d](/filings/0001493152-26-024184.md) | [741](/filings/0001641172-25-021487.md) | [(43.4)](/filings/0001493152-25-020604.md) | [311](/filings/0001493152-26-004738.md) | [3,961 d](/filings/0001493152-26-024184.md) | [1,226](/filings/0001493152-26-035447.md) |
| Diluted EPS | $ per share | [0.05](/filings/0001641172-25-021487.md) | [0.13](/filings/0001493152-25-020604.md) | [0.01](/filings/0001493152-26-004738.md) | not reported | [0.05](/filings/0001493152-26-035447.md) | [0.00](/filings/0001493152-25-020604.md) | [0.02](/filings/0001493152-26-004738.md) | not reported | [0.09](/filings/0001493152-26-035447.md) |
| Basic EPS | $ per share | [0.05](/filings/0001641172-25-021487.md) | [0.13](/filings/0001493152-25-020604.md) | [0.01](/filings/0001493152-26-004738.md) | not reported | [0.05](/filings/0001493152-26-035447.md) | [0.00](/filings/0001493152-25-020604.md) | [0.02](/filings/0001493152-26-004738.md) | not reported | [0.09](/filings/0001493152-26-035447.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss, us-gaap:ProfitLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-03-31) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | period not labelled (2024-12-31) | FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | [1.1](/filings/0001641172-25-017162.md) | not reported | not reported | not reported | [2.9](/filings/0001641172-25-017162.md) | [5.9](/filings/0001641172-25-021487.md) | [6.2](/filings/0001493152-25-020604.md) | [6.2](/filings/0001493152-26-004738.md) | [5.2](/filings/0001493152-26-035447.md) | [4.3](/filings/0001493152-26-035447.md) |
| Current assets | $m | not reported | [9.3](/filings/0001641172-25-017162.md) | not reported | not reported | not reported | [13.0](/filings/0001493152-26-024184.md) | [16.3](/filings/0001641172-25-021487.md) | [16.6](/filings/0001493152-25-020604.md) | [16.6](/filings/0001493152-26-004738.md) | [16.5](/filings/0001493152-26-035447.md) | [16.4](/filings/0001493152-26-035447.md) |
| Total assets | $m | not reported | [21.4](/filings/0001641172-25-017162.md) | not reported | not reported | not reported | [28.3](/filings/0001493152-26-024184.md) | [32.0](/filings/0001641172-25-021487.md) | [32.2](/filings/0001493152-25-020604.md) | [32.4](/filings/0001493152-26-004738.md) | [34.5](/filings/0001493152-26-035447.md) | [35.5](/filings/0001493152-26-035447.md) |
| Current liabilities | $m | not reported | [4.7](/filings/0001641172-25-017162.md) | not reported | not reported | not reported | [6.5](/filings/0001493152-26-024184.md) | [6.3](/filings/0001641172-25-021487.md) | [6.1](/filings/0001493152-25-020604.md) | [6.1](/filings/0001493152-26-004738.md) | [4.3](/filings/0001493152-26-035447.md) | [4.1](/filings/0001493152-26-035447.md) |
| Total liabilities | $m | not reported | [7.4](/filings/0001641172-25-017162.md) | not reported | not reported | not reported | [12.4](/filings/0001493152-26-024184.md) | [11.6](/filings/0001641172-25-021487.md) | [11.3](/filings/0001493152-25-020604.md) | [11.2](/filings/0001493152-26-004738.md) | [9.3](/filings/0001493152-26-035447.md) | [9.0](/filings/0001493152-26-035447.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | [5.0](/filings/0001641172-25-017162.md) | [4.9](/filings/0001641172-25-021487.md) | [4.8](/filings/0001493152-25-020604.md) | [4.6](/filings/0001493152-26-004738.md) | [4.6](/filings/0001493152-26-024184.md) | [4.5](/filings/0001493152-26-035447.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | [0.3](/filings/0001641172-25-017162.md) | [0.7](/filings/0001641172-25-021487.md) | [0.6](/filings/0001493152-25-020604.md) | [0.4](/filings/0001493152-26-004738.md) | [0.4](/filings/0001493152-26-024184.md) | [0.4](/filings/0001493152-26-035447.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001641172-25-021487.md) | not reported | not reported | not reported | [0.0](/filings/0001493152-26-035447.md) | [0.0](/filings/0001493152-26-035447.md) |
| Shareholders' equity | $m | [9.6](/filings/0001641172-25-017162.md) | [13.9](/filings/0001641172-25-017162.md) | [14.6](/filings/0001493152-26-004738.md) | [16.3](/filings/0001493152-26-004738.md) | [16.7](/filings/0001493152-26-004738.md) | [15.9](/filings/0001493152-26-024184.md) | [20.4](/filings/0001641172-25-021487.md) | [21.0](/filings/0001493152-25-020604.md) | [21.2](/filings/0001493152-26-004738.md) | [25.2](/filings/0001493152-26-035447.md) | [26.5](/filings/0001493152-26-035447.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest, us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2024-06-30) | period not labelled (2024-09-30) | period not labelled (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(252)](/filings/0001641172-25-021487.md) | [48.3 d](/filings/0001493152-25-020604.md) | [(110) d](/filings/0001493152-26-004738.md) | [(190) d](/filings/0001493152-26-024184.md) | [(509)](/filings/0001493152-26-035447.md) | [400 d](/filings/0001493152-25-020604.md) | [241 d](/filings/0001493152-26-004738.md) | [(913) d](/filings/0001493152-26-024184.md) | [(679)](/filings/0001493152-26-035447.md) |
| Capital expenditure | $k | [2.0](/filings/0001641172-25-021487.md) | not reported | not reported | not reported | [42.4](/filings/0001641172-25-021487.md) | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2024-06-30) | period not labelled (2024-09-30) | period not labelled (2024-12-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [12.4](/filings/0001641172-25-021487.md) | [12.7](/filings/0001493152-25-020604.md) | [13.0](/filings/0001493152-26-004738.md) | [13.8](/filings/0001493152-26-035447.md) | [13.9](/filings/0001493152-25-020604.md) | [13.9](/filings/0001493152-26-004738.md) | [14.1](/filings/0001493152-26-035447.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 14,128,468 at 2026-07-30, from the cover of the [10-Q filed 2026-07-30](/filings/0001493152-26-035447.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.